Posted by Michael Wonder on 31 Jul 2024
PTC Therapeutics announces sepiapterin NDA submission to FDA
30 July 2024 - PTC Therapeutics announced today the submission of the sepiapterin new drug application to the US FDA.
The new drug application submission is for the treatment of paediatric and adult patients with phenylketonuria, including the full spectrum of ages and disease subtypes.
